Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma [0.03%]
给药间隔依从性对儿童白血病或淋巴瘤重组Erwinia天冬酰胺酶药物动力学结果的影响
Milre M Matherne,John C Panetta,Jaclyn Hopp et al.
Milre M Matherne et al.
Introduction: Treatment for pediatric acute lymphoblastic leukemia includes asparaginase as an integral component of therapy. Hypersensitivity reactions or silent inactivation to Escherichia coli (E. coli) formulations ma...
Thrombosis Across Female-Specific Malignancies: From Chemotherapy-Driven Risk to Prophylaxis and Drug Interactions [0.03%]
女性恶性肿瘤的血栓形成：从化疗引起的危险因素到预防和药物相互作用
Maryam Aghakouchakzadeh,Hessam Kakavand,Anne J Goldberg et al.
Maryam Aghakouchakzadeh et al.
Cancer-associated thrombosis (CAT) remains a leading cause of morbidity and mortality among patients with cancer. Female-specific malignancies such as breast, ovarian, endometrial, and cervical cancers exhibit distinct thrombotic profiles d...
Incidence of Acute Kidney Injury With the Use of Nafcillin Versus Oxacillin [0.03%]
使用那西灵与苯唑西林发生急性肾损伤的病例分析
Alejandro D Perez,Autumn L Brenner,Emilia Pieta et al.
Alejandro D Perez et al.
Background: Antistaphylococcal penicillins (ASPs) are highly effective against infections caused by methicillin-susceptible Staphylococcus aureus (MSSA). Nafcillin and oxacillin are ASPs with similar spectra of activity, ...
Comparative Study
Pharmacotherapy. 2026 May;46(5):e70145. DOI:10.1002/phar.70145 2026
Contemporary Immunosuppression in Simultaneous Heart-Kidney Transplantation: A United Network for Organ-Sharing Database Analysis [0.03%]
同期心脏-肾脏移植的免疫抑制现状：美国器官共享联合网络数据库分析
Xinyi Huang,William L Baker,Paolo C Colombo et al.
Xinyi Huang et al.
Background: Simultaneous heart-kidney transplantation (SHKT) has become increasingly common over the past decade, accompanied by evolving recipient characteristics and outcomes introduced by the 2018 United Network for Or...
Association of Human Leucocyte Antigen with Tacrolimus Pharmacokinetics in Renal Transplant Patients [0.03%]
人类白细胞抗原与肾移植受者的他克莫司药代动力学关系研究
Rashmi J Hemani,Amit S Joreja,Nitiraj B Shete et al.
Rashmi J Hemani et al.
Introduction: Tacrolimus (Tac or FK-506) is an immunosuppressive agent that inhibits T-cell activation and proliferation. It has a narrow therapeutic index and shows inter-patient variabilities in its plasma concentration...
Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review [0.03%]
基于肠促胰素的治疗暴食症的方法-系统性综述
Raechel T White,Penelope Henriquez,Britnee Innocent et al.
Raechel T White et al.
Introduction: Binge eating disorder (BED) is a common psychiatric condition associated with psychological and cardiometabolic morbidity. Psychotherapy remains a core treatment modality while pharmacologic agents such as l...
SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis [0.03%]
急性肾损伤后钠葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂的使用：系统评价和meta分析
Erin F Barreto,Yessie A Garcia-Nieves,Evan C Johnson et al.
Erin F Barreto et al.
Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are nephroprotective and their use is recommended for adults with chronic kidney disease (CKD). The role of SGLT2i and GLP-1 RAs i...
C Lindsay DeVane
C Lindsay DeVane
Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis [0.03%]
单药治疗之外：GLP-1受体激动剂与SGLT2抑制剂联合用药对肾生物标志物的优越疗效：系统评价和Meta分析
Aya M AbdelMagid,Ahmed M Kamel,Samar F Farid
Aya M AbdelMagid
Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage renal diseases. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) confer renoprotection; however, emerging ...
Treatment Adherence to Oral Direct-Acting Antiviral Agents in Hepatitis C Infection [0.03%]
丙型肝炎病毒感染口服直接抗病毒药物的治疗顺应性
Javeria Khalid,Jieni Li,Rajender R Aparasu
Javeria Khalid
Background: Optimal adherence to second-generation direct-acting antiviral agents (DAAs) is crucial for preventing disease progression and reducing treatment resistance in patients with Hepatitis C virus (HCV). Therefore,...